Locate Bio obtains multiple late stage orthobiologics assets from RCSI
By Nikita Chaurasia  Date: 2020-09-23

Locate Bio obtains multiple late stage orthobiologics assets from RCSI

Regenerative medicine major, Locate Bio, has reportedly announced its in-licensing of several late stage orthobiologics assets from the RCSI University of Medicine and Health Sciences.

Sources state that the technologies created by the RCSI Tissue Engineering Research Group have wide human and pre-clinical data which efficaciously demonstrates their effectiveness in the treatment of both, soft and hard, tissues. The RCSI licensing transaction comprises natural collagen-based, best in class, and proprietary delivery technologies, that have been developed into numerous products for the regeneration of cartilage tissues, regeneration of bone, and the treatment of infections.

According to John von Benecke, the CEO of Locate Bio, the company is thrilled by the addition of these late stage, high-quality, and complementary products to its portfolio. He has further stated that this is a significant step in the company’s drive towards the development of a world leading orthobiologics enterprise, with its key platforms now covering numerous key areas across the clinical use waterfront.

Locate Bio continues to make excellent advancement toward spinal fusion with its lead product and eagerly looks ahead towards bringing these new assets via the process of regulatory approval in the forthcoming years, added Benecke.

Reliable sources state that Locate’s in-licencing of the assets from RCSI delivers additional breadth and depth to its existing orthobiologics portfolio, further accelerating its route to market. The company is reportedly in search of additional in-licencing or complementary acquisition opportunities that would widen its portfolio of giving surgeons the choice of best-in-class products and technologies that address the existing challenges of present products, also meeting the specific patient clinical requirement.

Ian Wilding, the Chairman at Locate Bio, has stated that the acquisition of these late stage orthobiologics assets progresses Locate’s aspirations and is another significant step in the company’s strategy towards the development of a complementary and differentiated portfolio of innovative products, with high value, strong IP, and a well-state path to market.

 

Source Credits:

https://www.locatebio.com/locate-bio-acquires-complementary-late-stage-orthobiologics-assets/

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

New York planning on direct purchase of Pfizer’s COVID-19 vaccines
New York planning on direct purchase of Pfizer’s COVID-19 vaccines
By Nikita Chaurasia

In recent developments, Governor of New York, Andrew Cuomo has reportedly issued a letter to the CEO of American drug maker Pfizer Inc., Albert Bourla, requesting for direct purchase of COVID-19 vaccine doses. Although the company is not bound to any...

Mayo Clinic Laboratories forms alliance with American Hospital Dubai
Mayo Clinic Laboratories forms alliance with American Hospital Dubai
By Nikita Chaurasia

In recent developments, Minnesota-based Mayo Clinic Laboratories and American Hospital Dubai are reportedly planning on entering a strategic alliance which is aimed at enhancing advanced laboratory diagnostic services in Dubai. Under the terms of th...

LTI, IBM extend global partnership to spearhead digital transformation
LTI, IBM extend global partnership to spearhead digital transformation
By Nikita Chaurasia

The New York-headquartered IBM Corp., with its global partner Larsen Toubro Infotech, an Indian global IT solutions & services company, are planning to extend their multi-year partnership, in a bid to enable companies to revolutionize the busines...

Algae cultivator Qualitas Health raises USD 10 million in funding round
Algae cultivator Qualitas Health raises USD 10 million in funding round
By Nikita Chaurasia

In recent developments, privately held food and nutrition company Qualitas Health Inc. has reportedly secured USD 10 million in venture funds, as it looks to broaden the reach of its plant-based protein and omega-3 business. The company was appraised...

China touts plans of launching national ETS to attain carbon neutrality
China touts plans of launching national ETS to attain carbon neutrality
By Nikita Chaurasia

According to reliable sources, the Chinese government is expected to launch the much anticipated national emission trade scheme (ETS) by mid-2021 as a part of the country’s efforts of achieving carbon-neutrality by the year 2060, through market...